Biomirex Inc. is a drug discovery company that is focused on the development of antibody-based therapeutics. Biomirex' core technology is a set of antigen presentation platforms specifically designed for complex membrane proteins such as G-Protein Coupled Receptors, amino acid and drug transporters, ion channels and alike. The Biomirex’s platforms in combination with phage display technology constitute a powerful engine for isolation of fully human antibodies.
The Company was established on the basis of technology developed at Harvard Medical School by founding scientist, Chairman and CEO of the company Dr. Tajib Mirzabekov. This technology enables the display of complex cell surface proteins in highly concentrated, purified form and in their native conformation so that they can be used as immunogens for vaccination and for antibody selection from in phage display libraries. The company is constantly renewing and updating its phage display antibody libraries as well as developing its alternative scaffold libraries.
Biomirex’ target display platforms allow to extract the target comlex integral membrane membrane proteins in their native conformation and display it in a highly purified form on nano-particle beads. This allows further amplification of the signal to as much as 10% of the surface area of the particles and thereby makes it readily available for recognition within a phage display system or as an immunogen.